Population Prevalence of High Dose Paracetamol in Dispensed Paracetamol/opioid Prescription Combinations: an Observational Study

Overview

Journal BMC Clin Pharmacol

Publisher Biomed Central

Specialty Pharmacology

Date 2012 Jun 20

PMID 22709372

Citations 21

Authors

Roderick Clark

Judith E Fisher

Ingrid S Sketris

Grace M Johnston

Affiliations

Soon will be listed here.

Abstract

Background: Paracetamol (acetaminophen) is generally considered a safe medication, but is associated with hepatotoxicity at doses above doses of 4.0 g/day, and even below this daily dose in certain populations.

Methods: The Nova Scotia Prescription Monitoring Program (NSPMP) in the Canadian province of Nova Scotia is a legislated organization that collects dispensing information on all out-of-hospital prescription controlled drugs dispensed for all Nova Scotia residents. The NSPMP provided data to track all paracetamol/opioids redeemed by adults in Nova Scotia, from July 1, 2005 to June 30, 2010. Trends in the number of adults dispensed these prescriptions and the numbers of prescriptions and tablets dispensed over this period were determined. The numbers and proportions of adults who filled prescriptions exceeding 4.0 g/day and 3.25 g/day were determined for the one-year period July 1, 2009 to June 30, 2010. Data were stratified by sex and age (<65 versus 65+).

Results: Both the number of prescriptions filled and the number of tablets dispensed increased over the study period, although the proportion of the adult population who filled at least one paracetamol/opioid prescription was lower in each successive one-year period. From July 2009 to June 2010, one in 12 adults (n = 59,197) filled prescriptions for over 13 million paracetamol/opioid tablets. Six percent (n = 3,786) filled prescriptions that exceeded 4.0 g/day and 18.6% (n = 11,008) exceeded 3.25 g/day of paracetamol at least once. These findings exclude non-prescription paracetamol and paracetamol-only prescribed medications.

Conclusions: A substantial number of individuals who redeem prescriptions for paracetamol/opioid combinations may be at risk of paracetamol-related hepatotoxicity. Healthcare professionals must be vigilant when prescribing and dispensing these medications in order to reduce the associated risks.

Citing Articles

Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.

Nasir N, Khanum I, Habib K, Wagley A, Arshad A, Majeed A Hepatol Forum. 2024; 5(3):139-149.

PMID: 39006140 PMC: 11237249. DOI: 10.14744/hf.2023.2023.0025.

Elderly mice with history of acetaminophen intoxication display worsened cognitive impairment and persistent elevation of astrocyte and microglia burden.

Catumbela C, Morales R Sci Rep. 2024; 14(1):14205.

PMID: 38902507 PMC: 11190293. DOI: 10.1038/s41598-024-65185-z.

Unveiling the power of microenvironment in liver regeneration: an in-depth overview.

Hu Y, Wang R, An N, Li C, Wang Q, Cao Y Front Genet. 2023; 14:1332190.

PMID: 38152656 PMC: 10751322. DOI: 10.3389/fgene.2023.1332190.

Acetaminophen-induced liver injury at therapeutic doses in a young adult: a case report.

Tajirika S, Yamamoto M, Matsushita T, Yamada T, Shimizu M Clin J Gastroenterol. 2023; 17(1):130-136.

PMID: 37964179 DOI: 10.1007/s12328-023-01883-x.

Association of FDA Mandate Limiting Acetaminophen (Paracetamol) in Prescription Combination Opioid Products and Subsequent Hospitalizations and Acute Liver Failure.

Orandi B, McLeod M, Maclennan P, Lee W, Fontana R, Karvellas C JAMA. 2023; 329(9):735-744.

PMID: 36881033 PMC: 9993184. DOI: 10.1001/jama.2023.1080.

References

Myers R, Li B, Shaheen A . Emergency department visits for acetaminophen overdose: a Canadian population-based epidemiologic study (1997-2002). CJEM. 2007; 9(4):267-74. DOI: 10.1017/s1481803500015153. View

Krenzelok E . The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol (Phila). 2009; 47(8):784-9. DOI: 10.1080/15563650903232345. View

Myers R, Li B, Fong A, Shaheen A, Quan H . Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995 to 2004. BMC Public Health. 2007; 7:143. PMC: 1931590. DOI: 10.1186/1471-2458-7-143. View

Fishman S, Gilson A . Commentary to Michna et al.: The elephant in the room: hydrocodone/acetaminophen combination compounds and the substitution effect. Pain Med. 2010; 11(3):379-81. DOI: 10.1111/j.1526-4637.2010.00810.x. View

Sabate M, Ibanez L, Perez E, Vidal X, Buti M, Xiol X . Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol. 2011; 11:80. PMC: 3150324. DOI: 10.1186/1471-230X-11-80. View

Barozzi N, Tett S . Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market. Clin Rheumatol. 2009; 28(5):509-19. DOI: 10.1007/s10067-008-1077-8. View

Buckwalter J, Martin J . Osteoarthritis. Adv Drug Deliv Rev. 2006; 58(2):150-67. DOI: 10.1016/j.addr.2006.01.006. View

Michna E, Duh M, Korves C, Dahl J . Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med. 2010; 11(3):369-78. DOI: 10.1111/j.1526-4637.2010.00811.x. View

Graham G, Day R, Graudins A, Mohamudally A . FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?. Inflammopharmacology. 2010; 18(2):47-55. DOI: 10.1007/s10787-010-0036-6. View

10.

Moling O, Cairon E, Rimenti G, Rizza F, Pristera R, Mian P . Severe hepatotoxicity after therapeutic doses of acetaminophen. Clin Ther. 2006; 28(5):755-60. DOI: 10.1016/j.clinthera.2006.05.002. View

11.

Lee W, Squires Jr R, Nyberg S, Doo E, Hoofnagle J . Acute liver failure: Summary of a workshop. Hepatology. 2008; 47(4):1401-15. PMC: 3381946. DOI: 10.1002/hep.22177. View

12.

Kirchheiner J, Schmidt H, Tzvetkov M, Keulen J, Lotsch J, Roots I . Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2006; 7(4):257-65. DOI: 10.1038/sj.tpj.6500406. View

13.

Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G . A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 2007; 37(6):410-5. DOI: 10.1111/j.1872-034X.2007.00072.x. View

14.

Furlan A, Reardon R, Weppler C . Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ. 2010; 182(9):923-30. PMC: 2882451. DOI: 10.1503/cmaj.100187. View

15.

MacDonald N, MacLeod S . Has the time come to phase out codeine?. CMAJ. 2010; 182(17):1825. PMC: 2988526. DOI: 10.1503/cmaj.101411. View

16.

Claridge L, Eksteen B, Smith A, Shah T, Holt A . Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults. BMJ. 2010; 341:c6764. DOI: 10.1136/bmj.c6764. View

17.

McClain C, Price S, Barve S, Devalarja R, Shedlofsky S . Acetaminophen hepatotoxicity: An update. Curr Gastroenterol Rep. 2000; 1(1):42-9. DOI: 10.1007/s11894-999-0086-3. View

18.

Bower W, Johns M, Margolis H, Williams I, Bell B . Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007; 102(11):2459-63. DOI: 10.1111/j.1572-0241.2007.01388.x. View

19.

Larson A, Polson J, Fontana R, Davern T, Lalani E, Hynan L . Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005; 42(6):1364-72. DOI: 10.1002/hep.20948. View

20.

James L, Mayeux P, Hinson J . Acetaminophen-induced hepatotoxicity. Drug Metab Dispos. 2003; 31(12):1499-506. DOI: 10.1124/dmd.31.12.1499. View